Erica is the Senior Scientific Director at Myosin Therapeutics, where she supports the company’s preclinical and translational programs, overseeing in vivo efficacy and safety pharmacology studies, contributing to medical writing and regulatory document preparation, and coordinating with clinical experts and CRO partners.

She earned her PhD at the University of Virginia with training in learning, memory, and anxiety. She joined Dr. Courtney Miller’s lab at UF Scripps in 2010, expanding her expertise in neuropsychiatric disease biology and behavioral pharmacology—including foundational work demonstrating that methamphetamine-associated memories can be disrupted through actin dynamics and nonmuscle myosin II inhibition.

At Myosin, she has helped advance MT-110 and supports MT-125 development through IND-enabling preparation, medical writing, and cross-functional program coordination.

Kevin McCabe serves as Lead Counsel to Myosin Therapeutics, advising the company on corporate governance, partnering and contracting, IP strategy, and risk management.

Kevin is a seasoned life-sciences legal executive with deep experience in IP, exclusivity/lifecycle strategy, and complex transactions. He previously served at TherapeuticsMD as Associate General Counsel and later Chief Exclusivity Officer.

He has also held senior in-house IP leadership roles at Teva Pharmaceuticals, Allergan, and Actavis. Earlier in his career, he practiced in Washington, DC, serving as a partner at Sterne, Kessler, Goldstein & Fox and an associate at Finnegan.

Kim is a pharmaceutical executive and clinical operations strategist with 30+ years of experience leading global R&D programs across sponsors, CROs, and vendor organizations.

She has built and led high-performing project management teams, scaled decentralized clinical trial (DCT) capabilities across 60+ countries, and supported numerous NDA submissions across therapeutic areas including CNS, oncology, and rare diseases.

She is the Founder and CEO of BioClinical Solutions and serves as Head of Clinical Operations at Myosin Therapeutics. Previously, she helped build Oncology and CNS business units at Paragon Biomedical and led decentralized trial operations at Marken, integrating direct-to-patient logistics and home healthcare to improve trial access.

Minghai is a drug discovery scientist with expertise spanning neurodegeneration, immunology, and oncology. He spent more than 13 years at The Scripps Research Institute in Florida, progressing from postdoctoral fellow to staff scientist, where he investigated neurotoxicity driven by misfolded proteins and advanced therapeutic strategies for neurodegenerative disease.

He later served as Director of Biology at Vova Ida Therapeutics, leading preclinical discovery programs, and is a co-inventor on multiple patents.

Since 2022, Minghai has advanced MT-125 at Myosin Therapeutics, leading mechanism-of-action work, combination studies, formulation activities, and CRO/consultant collaborations to support development in orphan cancers.

Valerie is a regulatory affairs leader with 40+ years of experience across GLP toxicology, pharmaceutical R&D, and global regulatory strategy.

She began her career in GLP toxicology labs and on NIH/NCI contract projects, then transitioned into pharma R&D supporting IND and NDA submissions before moving into Regulatory Affairs as her primary focus.

Most recently, she served as Vice President, Regulatory Affairs at TherapeuticsMD and now serves as an independent consultant and Head of Regulatory for Myosin Therapeutics.

A native of the Bay Area, Dr. Miller is a neuroscientist focused on drug discovery and development with expertise in cytoskeletal dynamics. In 2009 she joined Scripps Research and established a research program focused on developing neurotherapeutics.

Dr. Miller’s laboratory made the initial discovery of nonmuscle myosin II’s (NMII) therapeutic potential and was recognized for these efforts with a Presidential Early Career Award for Scientists and Engineers (PECASE), presented by President Obama in 2016.

To advance the therapeutic potential of molecular motors like NMII, Dr. Miller launched a collaborative medication development program with Drs. Griffin and Kamenecka. In addition to Dr. Miller’s scientific expertise, she has training in venture capital and was named a Kauffman Finalist in Venture Investment.

Trained in biophysical chemistry, has spent the last 31 years performing drug discovery and development in academia and the biotechnology and pharmaceutical industry. During his tenure at Merck, as Senior Director of Chemistry, his research team made significant contributions towards the discovery of MK-0431, a DPP4 inhibitor now in clinical use, and towards clinical development of DMP-777, an elastase inhibitor for treatment of cystic fibrosis.

From 2002 to 2004, he was CSO of ExSAR, a biotech company focused on the development of chemical chaperones for protein misfolding disorders.

In 2004, he joined Scripps Research, where his research is focused on protein structure and function, particularly on mutational- and ligand-mediated alterations in protein structural plasticity, as well as quantitative SAR to facilitate lead optimization of molecules targeting therapeutic proteins.

Trained in synthetic organic chemistry, has spent the last 22 years performing drug discovery and development in academia and the pharmaceutical industry. At Sloan-Kettering, Dr. Kamenecka contributed to the development of novel epothilone analogs for the treatment of breast cancer, which was brought to the market in 2007.

At Merck, his group delivered proof-of-concept molecules for novel targets and clinical candidates for established programs focused on a variety of indications.

Upon rejoining academia in 2004 at Scripps Research, his group has continued to work on a diverse set of targets from kinases, GPCR’s, ion channels, to nuclear receptors for a variety of indications, including SUD and cancer.

In 2017, he co-founded Eolas Therapeutics with Dr. Paul Kenny to advance an SUD program which was licensed to pharma and is now in Ph1 clinical trials.

Dr. Smith is a BioPharma Executive, Board Director and Clinical/Scientific Advisor. Her breadth of experience covers 100+ clinical trials and 20+ regulatory approvals in multiple jurisdictions including FDA (USA), EMA (Europe), TGA (Australia), ANVISA (Brazil), and PMDA (Japan).

Dr. Smith has held various clinical and business roles over the past 20 years including President, CEO, Global Head R&D, and Chief Medical Officer (CMO).

Dr. Smith currently serves on the Board of Sangamo Tx (SGMO), Skye Bioscience (SKYE) and Context (CNTX), and has been closely involved in the completion of over $15B in corporate M&A activities.

Bruce Pascal is a computational biology and software engineering leader with more than two decades of experience building informatics platforms for genomics, proteomics, and drug discovery.

He was a founding member and Director of IT at Biosift, where he co-invented Scintilla, an early genomic data integration system. He later helped found Ananomouse Corporation and played a central role in developing Bloodhound, a kinship analysis platform later incorporated into CODIS II and used by the U.S. Department of Justice.

As Bioinformatics Director at Scripps Florida, he led core analysis and software engineering efforts and developed tools including HDX Workbench. In 2017, he founded Omics Informatics LLC, providing scientific software development services to research organizations worldwide.